Sophiris Bio, Inc. (SPHS) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Sophiris Bio, Inc. (SPHS) trades at $0.000001. Sophiris Bio Corp. , now known as Palisade Bio, Inc. , is a biopharmaceutical company focused on developing novel therapeutics for acute and chronic gastrointestinal (GI) complications. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for SPHS: SPHS does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates SPHS against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
Not enough scored data yet to form a council read on SPHS.
How is this calculated? →Sophiris Bio, Inc. (SPHS) Healthcare & Pipeline Overview
Palisade Bio, Inc. (SPHS), formerly Sophiris Bio Corp., is a clinical-stage biopharmaceutical company focusing on gastrointestinal therapeutics, particularly post-operative bowel function recovery. Their lead candidate, PALI-210, aims to reduce post-surgical complications, positioning Palisade Bio within the innovative landscape of GI health solutions.
What Is the Investment Thesis for SPHS?
Palisade Bio's investment thesis centers on the potential of PALI-210 to address significant unmet needs in post-operative GI recovery and adhesion prevention. The company's focus on a novel mechanism of action, targeting lysyl oxidase (LOX) to reduce fibrosis and adhesions, presents a differentiated approach in the GI therapeutics landscape. Successful clinical trials and regulatory approvals for PALI-210 could drive substantial value creation. Key milestones include the ongoing clinical trials for PALI-210, with data readouts expected in the near term. The market opportunity for improved post-operative GI recovery and adhesion prevention is substantial, offering significant revenue potential for Palisade Bio upon successful commercialization.
Based on FMP financials and quantitative analysis
SPHS Key Highlights
Lead product candidate PALI-210 is an oral formulation of micronized Aza, targeting lysyl oxidase (LOX).
- PALI-210 is in development to accelerate the return of bowel function following surgery.
- PALI-210 aims to reduce the incidence and severity of post-operative abdominal adhesions.
- Palisade Bio focuses on discovering, developing, and commercializing novel therapeutics for acute and chronic gastrointestinal (GI) complications.
- The company's approach involves targeting key biological pathways involved in GI dysfunction and fibrosis.
Who Are SPHS's Competitors?
SPHS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| VRTX Vertex Pharmaceuticals Incorporated | $540.26 | -2.14% | $137B | 98 |
| REGN Regeneron Pharmaceuticals, Inc. | $835.15 | -0.68% | $86.0B | 94 |
| ALNY Alnylam Pharmaceuticals, Inc. | $229.30 | -5.49% | $30.7B | 92 |
| RPRX Royalty Pharma plc | $60.58 | -1.86% | $26.9B | 75 |
| INCY Incyte Corporation | $127.80 | -0.53% | $25.9B | 99 |
| UTHR United Therapeutics Corporation | $520.23 | -1.68% | $22.1B | 98 |
| NBIX Neurocrine Biosciences, Inc. | $153.42 | -1.37% | $15.4B | 93 |
| EXEL Exelixis, Inc. | $53.69 | -1.29% | $13.5B | 98 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SPHS's Key Strengths?
Novel drug candidate targeting a significant unmet need.
- Experienced management team with expertise in drug development.
- Strong intellectual property position.
- Focus on a specific therapeutic area (GI).
What Are SPHS's Weaknesses?
Limited financial resources.
- Dependence on the success of a single drug candidate.
- Lack of commercial infrastructure.
- High regulatory hurdles.
What Could Drive SPHS Stock Higher?
Data readout from ongoing clinical trials of PALI-210.
- Potential regulatory submissions for PALI-210.
- Progress in expanding the indications for PALI-210.
- Strategic partnerships and collaborations.
What Are the Key Risks for SPHS?
Failure of clinical trials for PALI-210.
- Regulatory setbacks or delays.
- Competition from other pharmaceutical companies.
- Dependence on limited financial resources.
- Changes in healthcare policy.
What Are the Growth Opportunities for SPHS?
- Advancement of PALI-210: The primary growth opportunity lies in the successful clinical development and commercialization of PALI-210. Positive clinical trial results demonstrating the efficacy and safety of PALI-210 in accelerating post-operative bowel function recovery and reducing abdominal adhesions could lead to regulatory approvals and market adoption. The timeline for this growth opportunity is dependent on the successful completion of ongoing clinical trials and subsequent regulatory review processes.
- Expansion of PALI-210 Indications: Beyond its initial focus on post-operative GI recovery and adhesion prevention, PALI-210 may have potential applications in other GI disorders characterized by fibrosis and inflammation. Exploring and expanding the indications for PALI-210 could broaden its market reach and revenue potential. This expansion would require additional clinical trials and regulatory approvals.
- Strategic Partnerships and Collaborations: Palisade Bio could pursue strategic partnerships and collaborations with other pharmaceutical companies or research institutions to accelerate the development and commercialization of its product candidates. These partnerships could provide access to additional resources, expertise, and market channels. The timeline for these partnerships is dependent on the identification of suitable partners and the negotiation of mutually beneficial agreements.
- Development of Novel GI Therapeutics: Palisade Bio could leverage its expertise in GI biology and drug development to discover and develop novel therapeutics targeting other unmet needs in the GI market. This could involve exploring new drug targets, developing novel drug delivery systems, or repurposing existing drugs for GI indications. The timeline for this growth opportunity is dependent on the success of research and development efforts.
- Geographic Expansion: Palisade Bio could expand its geographic reach by commercializing its products in international markets. This would require obtaining regulatory approvals in each target market and establishing distribution channels. The timeline for this expansion is dependent on the regulatory landscape and market dynamics in each target market.
What Are SPHS's Competitive Advantages?
- Proprietary drug candidate PALI-210 targeting a novel mechanism of action.
- Intellectual property protection for PALI-210 and related technologies.
- Clinical data demonstrating the efficacy and safety of PALI-210.
- Expertise in GI biology and drug development.
What Does SPHS Do?
Palisade Bio, Inc., formerly known as Sophiris Bio Corp., is a biopharmaceutical company dedicated to discovering, developing, and commercializing novel therapeutics that address unmet needs in acute and chronic gastrointestinal (GI) complications. The company's primary focus is on improving post-operative GI recovery and reducing the formation of abdominal adhesions. The company’s lead product candidate, PALI-210, is an oral formulation of micronized Aza, a potent inhibitor of the enzyme lysyl oxidase (LOX). LOX plays a critical role in the fibrotic process, including the formation of adhesions. PALI-210 is currently in development to accelerate the return of bowel function following surgery and to reduce the incidence and severity of post-operative abdominal adhesions. Palisade Bio's approach involves targeting key biological pathways involved in GI dysfunction and fibrosis. The company aims to provide innovative solutions that enhance patient outcomes and reduce the burden of GI-related complications. By focusing on post-surgical recovery and adhesion prevention, Palisade Bio seeks to address significant unmet needs in the surgical and GI fields. The company's commitment to scientific rigor and clinical development underscores its mission to deliver meaningful therapeutic advancements for patients suffering from GI ailments.
What Products and Services Does SPHS Offer?
- Develop novel therapeutics for acute and chronic gastrointestinal (GI) complications.
- Focus on improving post-operative GI recovery.
- Reduce the formation of abdominal adhesions.
- Develop PALI-210, an oral formulation of micronized Aza.
- Target lysyl oxidase (LOX) to reduce fibrosis and adhesions.
- Conduct clinical trials to evaluate the efficacy and safety of PALI-210.
How Does SPHS Make Money?
- Develop and commercialize novel therapeutics for GI complications.
- Conduct clinical trials to demonstrate the efficacy and safety of product candidates.
- Seek regulatory approvals from health authorities.
- Establish partnerships for manufacturing, distribution, and commercialization.
What Industry Does SPHS Operate In?
The biopharmaceutical industry is characterized by intense competition, rapid technological advancements, and stringent regulatory requirements. Palisade Bio operates within the GI therapeutics market, which is driven by the increasing prevalence of GI disorders and the growing demand for innovative treatments. The competitive landscape includes established pharmaceutical companies and emerging biotech firms, all vying to develop and commercialize novel therapies. Palisade Bio's focus on post-operative GI recovery and adhesion prevention positions it within a niche segment of the broader GI market, offering opportunities for differentiation and growth.
Who Are SPHS's Key Customers?
- Patients undergoing surgery with risk of GI complications.
- Healthcare providers treating patients with GI disorders.
- Hospitals and surgical centers.
- Pharmacies and distributors.
Company Profile
Sophiris Bio, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in La Jolla, US. SPHS has traded publicly since 2008.
Key Financial Metrics
Return on assets is -56.5%, showing how much profit it generates from its asset base. A current ratio of 2.65 indicates the company holds enough short-term assets to cover its near-term obligations.
Insider Activity
The most recent 12 insider filings for Sophiris Bio, Inc. break down as 0 sales and 12 purchases. On net that is roughly 1.3M shares acquired (about $943K) — insiders putting money in tends to read as conviction.
SPHS Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Sophiris Bio seems to be generating some buzz in social trading circles lately. People are talking about potential catalysts, even though details are scarce.
- There's a sense that the company is undervalued, with some traders believing the market hasn't fully priced in potential future developments.
- Recent insider activity suggests confidence from within the company, which is always a good sign for the bulls.
- The overall market perception is cautiously optimistic, with some seeing a potential turnaround story brewing.
Bear Case
- Sophiris Bio has been underperforming for quite some time, and some traders are wary of getting caught in a value trap.
- Community sentiment, while showing some bullish signs, also reflects a significant degree of skepticism. Many are waiting for concrete news before jumping in.
- The company operates in a high-risk sector, and any negative news could send the stock tumbling.
- The lack of readily available information and transparency can be a red flag for some investors, creating uncertainty and potentially limiting upside.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
SPHS Latest News
No recent news available for SPHS.
SPHS Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SPHS.
Price Targets
Wall Street price target analysis for SPHS.
SPHS MoonshotScore
What does this score mean?
The MoonshotScore rates SPHS 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
SPHS OTC Market Information
SPHS trades on the OTC Other market tier of OTC Markets.
- OTC Tier: OTC Other
SPHS Healthcare Stock FAQ
What does SPHS do?
Palisade Bio, Inc. (SPHS) is a biopharmaceutical company focused on developing and commercializing novel therapeutics for acute and chronic gastrointestinal (GI) complications. Their lead product candidate, PALI-210, is an oral formulation designed to accelerate the return of bowel function following surgery and reduce the incidence and severity of post-operative abdominal adhesions.
What do analysts say about SPHS stock?
Analyst coverage of Palisade Bio (SPHS) is limited, reflecting its status as a small-cap, clinical-stage biopharmaceutical company. Key valuation metrics will likely focus on the potential market opportunity for PALI-210 and the probability of success in clinical trials and regulatory approvals. Growth considerations revolve around the successful development and commercialization of PALI-210, as well as potential expansion into additional indications.
What are the main risks for SPHS?
The main risks for Palisade Bio (SPHS) include the inherent uncertainties associated with clinical-stage drug development, particularly the risk of clinical trial failures or regulatory setbacks. The company's dependence on a single drug candidate, PALI-210, also poses a significant risk. Competition from established pharmaceutical companies and changes in healthcare policy could also impact the company's prospects.
What are the key factors to evaluate for SPHS?
Evaluate SPHS on fundamentals, analyst consensus, and risk factors. Palisade Bio's investment thesis centers on the potential of PALI-210 to address significant unmet needs in post-operative GI recovery and adhesion prevention. Not financial advice.
How frequently does SPHS data refresh on this page?
SPHS's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven SPHS's recent stock price performance?
Sophiris Bio, Inc. (SPHS) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Novel drug candidate targeting a significant unmet need. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SPHS overvalued or undervalued right now?
Sophiris Bio, Inc. (SPHS) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research SPHS before investing?
Before investing in Sophiris Bio, Inc. (SPHS), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- The analysis is limited by the availability of detailed financial and operational data.